Edition:
United States

Chromadex Corp (CDXC.OQ)

CDXC.OQ on NASDAQ Stock Exchange Capital Market

4.43USD
4:00pm EDT
Change (% chg)

$-0.13 (-2.85%)
Prev Close
$4.56
Open
$4.50
Day's High
$4.51
Day's Low
$4.43
Volume
21,255
Avg. Vol
49,752
52-wk High
$5.00
52-wk Low
$2.79

Latest Key Developments (Source: Significant Developments)

Pioneer Step Holdings Limited Reports 9.6 Percent Stake In Chromadex As Of May 9
Monday, 13 May 2019 01:20pm EDT 

May 13 (Reuters) - Pioneer Step Holdings Ltd::PIONEER STEP HOLDINGS LIMITED REPORTS 9.6 PERCENT STAKE IN CHROMADEX CORP AS OF MAY 9, 2019 - SEC FILING.PIONEER STEP HOLDINGS LIMITED - HAD PREVIOUSLY REPORTED 8.1 PERCENT STAKE IN CHROMADEX CORP AS OF NOV 17, 2017.  Full Article

Chromadex Corporation Reports 2018 Financial Results
Thursday, 7 Mar 2019 04:01pm EST 

March 7 (Reuters) - Chromadex Corp ::ORATION REPORTS 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.15.Q4 SALES $9.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $9.1 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.14 -- REFINITIV IBES DATA.CONTINUE TO EXPECT COMPANY TO BE CASH FLOW BREAKEVEN BY Q4 OF 2019 OR EARLY 2020.  Full Article

Chromadex And Nestlé Health Science Sign Global Commercial License And Supply Deal
Thursday, 20 Dec 2018 04:05pm EST 

Dec 20 (Reuters) - Chromadex Corp ::CHROMADEX CORP. AND NESTLÉ HEALTH SCIENCE ENTER GLOBAL COMMERCIAL LICENSE AND SUPPLY AGREEMENT FOR TRU NIAGEN®.CHROMADEX - AGREEMENT PROVIDES NHSC EXCLUSIVE RIGHT TO INCLUDE CO'S PATENTED NICOTINAMIDE RIBOSIDE INGREDIENT TRU NIAGEN IN NHSC BRANDED MEDICAL NUTRITION.CHROMADEX CORP - AGREEMENT PROVIDES NHSC CO-EXCLUSIVE RIGHTS TO INCLUDE TRU NIAGEN IN CERTAIN PRODUCTS WITHIN CONSUMER HEALTH CATEGORY.CHROMADEX CORP - UNDER TERMS OF AGREEMENT, NHSC WILL MAKE AN UPFRONT PAYMENT OF $4 MILLION.CHROMADEX - UNDER AGREEMENT CO WILL RECEIVE CERTAIN COMMERCIAL MILESTONE PAYMENTS RELATED TO SALE OF TRU NIAGEN® TO NHSC AS WELL AS TIERED ROYALTIES.  Full Article

Chromadex Says Tru Niagen Daily Serving Strengthened Under FDA NDI Notification
Wednesday, 24 Oct 2018 06:30am EDT 

Oct 24 (Reuters) - Chromadex Corp ::TRU NIAGEN® DAILY SERVING STRENGTHENED UNDER FDA’S NDI NOTIFICATION.CHROMADEX - STRENGTHENED FLAGSHIP TRU NIAGEN (NICOTINAMIDE RIBOSIDE) NUTRIENT TO 150MG CAPSULES, TWO PER DAY.  Full Article

Chromadex Corp Appoints Rob Fried as Chief Executive Officer
Monday, 23 Apr 2018 04:05pm EDT 

April 23 (Reuters) - Chromadex Corp ::CHROMADEX APPOINTS FRANK JAKSCH AS EXECUTIVE CHAIRMAN, ROB FRIED AS CHIEF EXECUTIVE OFFICER AND KURT GUSTAFSON AS LEAD DIRECTOR.CHROMADEX CORP - JAKSCH SUCCEEDS STEPHEN ALLEN.CHROMADEX CORP - FRIED WILL SUCCEED FRANK JAKSCH AS CEO.  Full Article

Chromadex Files For Resale Of Up To 5.6 Mln Shares Of Common Stock By The Selling Stockholders
Thursday, 14 Dec 2017 05:06pm EST 

Dec 14 (Reuters) - Chromadex Corp ::CHROMADEX CORP FILES FOR RESALE OF UP TO 5.6 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING.  Full Article

ChromaDex Q3 loss per share $0.07 from continuing operations
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - ChromaDex Corp ::ChromaDex reports third quarter 2017 financial results.Q3 loss per share $0.07 from continuing operations.Q3 sales rose 55 percent to $6.1 million.  Full Article

Chromadex announces $23 mln private placement of common stock
Monday, 6 Nov 2017 06:30am EST 

Nov 6 (Reuters) - Chromadex Corp :Chromadex announces $23 million private placement of common stock.Chromadex Corp - in connection with investment, co agreed to sell 5.6 million shares of common stock at a per share price of $4.10​.Chromadex Corp - ‍net proceeds of investment expected to provide co added resources to accelerate plans related to nad+ in general, tru niagen in particular​.  Full Article

Chromadex Corp files for common stock‍​ offering by selling stockholders of up to $7.7 mln
Tuesday, 31 Oct 2017 04:59pm EDT 

Oct 31 (Reuters) - Chromadex Corp :Chromadex Corp files for common stock‍​ offering by selling stockholders of up to $7.7 million - SEC filing.  Full Article

Chromadex appoints Kevin Farr as new CFO
Monday, 9 Oct 2017 06:30am EDT 

Oct 9 (Reuters) - Chromadex Corp :Chromadex appoints Kevin Farr as new CFO.Chromadex Corp says ‍Chromadex expects that Thomas Varvaro will transition from Chromadex over coming months to pursue other opportunities​.  Full Article